ACTUATE THERAPEUTICS, INC. (ACTU) Earnings Signals & AI Vibe Check

Latest Filing: 10-K  |  Filed Mar 26, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for ACTUATE THERAPEUTICS, INC.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, ACTUATE THERAPEUTICS, INC.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does ACTUATE THERAPEUTICS, INC. actually do?
Answer:
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 (GSK-3). Its lead candidate, elraglusib, a small molecule GSK-3β inhibitor, has demonstrated a statistically significant improvement in median overall survival in a Phase 2 trial for first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) when combined with gemcitabine/nab-paclitaxel. Elraglusib is also being evaluated in pediatric cancers, with oral dosage forms under development for broader indications. The company has exclusively licensed elraglusib, originally developed through a collaboration between the University of Illinois-Chicago and Northwestern University.
Question:
What are ACTUATE THERAPEUTICS, INC.'s revenue drivers?
Answer:
The company has not generated revenue from product sales and expects to incur significant operating losses. Future revenue will depend on the successful development, regulatory approval, and commercialization of elraglusib.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required